Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04521231 · ClinicalTrials.gov registry record · Phase 1
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
A Phase 1 study of B Cell Precursor Acute Lymphoblastic Leukemia, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 281
- Enrollment target
- 20
- Study locations
NCT04521231: Recruiting Phase 1 study of B Cell Precursor Acute Lymphoblastic Leukemia, sponsored by Amgen.
NCT04521231 is a Phase 1 study of B Cell Precursor Acute Lymphoblastic Leukemia that is actively recruiting participants, run by Amgen. The registered enrollment target is 281 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (368% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04521231, a Phase 1 study of B Cell Precursor Acute Lymphoblastic Leukemia, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 281 participants
- Enrollment target
- 20
- Study locations
Study Summary
The Phase I part of the study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL), to determine the maximum tolerated dose (MTD), and recommended phase 2 dose(s) (RP2D) of SC administered blinatumomab. The Phase II part of the study will evaluate the safety, efficacy, and tolerability of SC blinatumomab for treatment of R/R B-ALL and Minimum Residual Disease Positive (MRD+) B-ALL in participants 12 years old and greater. It will also conduct a clinical pharmacokinetic (PK) evaluation of SC1 and SC2 blinatumomab formulations.
Conditions Studied
Interventions
- DRUG Blinatumomab
Study Locations (20)
New York
- New York University Grossman School of Medicine and New York University Langone Hospitals - New York
- Albert Einstein College of Medicine - Montefiore Medical Center - The Bronx
Washington
- Fred Hutchinson Cancer Center - Seattle
- Fred Hutchinson Cancer Center - Seattle
Other
- Instituto Alexander Fleming - Buenos Aires
- Cemic - Centro de Educacion Medica e Investigaciones Clinicas Norberto Quirno - Ciudad Autonoma Buenos Aires
New South Wales
- Sydney Childrens Hospital - Randwick
- Westmead Hospital - Westmead
California
- City of Hope National Medical Center - Duarte
Illinois
- University of Illinois Chicago - Chicago
Maryland
- Johns Hopkins University - Baltimore
Michigan
- C.S. Mott Children's Hospital - University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 281 participants |
| Start Date | 2021-01-04 |
| Est. Completion | 2029-05-25 |
| Phase | Phase 1 |
What NCT04521231 shows while recruiting
NCT04521231 is an interventional study that assigns participants to a tested intervention. The registered 281 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (368% higher).
The record links to 1 condition, with B Cell Precursor Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Blinatumomab is the first listed.
NCT04521231 names 20 study sites across 16 states, led by New York, Washington, Other.
Frequently Asked Questions
What is clinical trial NCT04521231 about?
NCT04521231 is a clinical study titled "A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL". The Phase I part of the study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL), to determine the maximum tolerated dose (MTD), and recommended phase 2 dose(s) (R...
What is the current status of trial NCT04521231?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 281 participants. The study started on 2021-01-04. Estimated completion is 2029-05-25.
What conditions does trial NCT04521231 study?
This clinical trial studies the following conditions: B Cell Precursor Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT04521231?
The interventions under investigation include: Blinatumomab (DRUG).
Who is sponsoring clinical trial NCT04521231?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04521231 being conducted?
This trial has 20 study locations across California, Illinois, Maryland, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04521231's enrollment target sits among peer trials
281 141st of 2000 higher than 1,860 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06190730 · 281 participants · NA
REmote Symptom COllection to improVE postopeRative Care
- NCT02860364 · 282 participants · NA
Comparing Hypothermic Temperatures During Hemiarch Surgery
- NCT04867395 · 282 participants · NA
A Multi-Phase Study Examining Hospital to Home Transitions for Children With Medical Complexity
- NCT05101070 · 282 participants · Phase 1
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI